GlassScriptPhysician profile
Yared Aklilu
NPI 1225034986
$14,713.18
in general payments reported to CMS, 2019-2025
20 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 86% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,187 · 2020: $1,822 · 2021: $2,457 · 2022: $2,027 · 2023: $2,223 · 2024: $1,916 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,193 · Education: $28.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,192.79 |
| Education | $28.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,254.25 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $3,037.87 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Janssen Biotech, INC. | $1,958.09 | 2019-2023 | Symtuza |
| Abbvie INC. | $1,347.11 | 2019-2025 | Dalvance, Avycaz, Mavyret |
| Merck Sharp & Dohme LLC | $1,016.60 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $1,002.96 | 2019-2025 | Arikayce, Brinsupri |
| Emd Serono, INC. | $500.05 | 2019-2025 | Serostim |
| Allergan, INC. | $406.52 | 2019-2020 | |
| Janssen Products, LP | $376.84 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $345.25 | 2019-2025 | Nuzyra |
| Astellas Pharma US INC | $332.53 | 2019-2022 | |
| Shionogi INC | $316.25 | 2020-2025 | Fetroja |
| Melinta Therapeutics, LLC | $285.53 | 2020-2025 | Rezzayo, Kimyrsa, Vabomere |
| La Jolla Pharmaceutical Company | $249.11 | 2021-2024 | Xerava, Xacduro |
| Theratechnologies INC. | $131.83 | 2022-2024 | Trogarzo, Egrifta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $53.89 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $39.58 | 2024-2025 | Zenpep |
| Cumberland Pharmaceuticals, INC. | $27.45 | 2025 | Vibativ |
| Mylan Institutional INC. | $17.32 | 2019 | |
| Nabriva Therapeutics, Plc | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yared Aklilu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.